CBD Oil for Dogs in the UK: Legal Status, Quality Standards & Best Options 2026

The UK CBD Pet Market in 2026: A Shifting Landscape

The market for CBD dog products in the United Kingdom has grown substantially since 2019, driven by a combination of genuine scientific interest, consumer demand for natural health options, and — it must be said — considerable marketing activity that has outpaced both the evidence and the regulatory framework.

For UK dog owners, the landscape has been further complicated by Brexit. Prior to January 2021, UK pet supplement products operated within the EU's harmonised feed regulations. Since then, the UK has developed its own regulatory trajectory — one that, in some respects, applies stricter interpretations than the EU framework to CBD products, and in others remains less clearly defined.

Understanding where CBD for dogs sits legally in the UK in 2026, and what quality markers to look for irrespective of regulatory status, is the purpose of this guide.

The VMD's Position: When CBD Becomes a Veterinary Medicine

The UK Veterinary Medicines Directorate (VMD) is the body responsible for regulating veterinary medicines in Great Britain. Its position on CBD is clear and consequential: any product containing CBD that is presented as having a therapeutic effect in animals — treating, preventing, or alleviating a condition — is classified as a veterinary medicine under the Veterinary Medicines Regulations 2013.

Veterinary medicines require a Marketing Authorisation (MA) before they can be legally placed on the UK market. As of 2026, no CBD-containing veterinary medicine holds a UK Marketing Authorisation. This means that any CBD product making explicit therapeutic claims for dogs — "reduces anxiety," "relieves joint pain," "treats epilepsy" — is technically operating outside the licensed veterinary medicine framework.

The practical consequence for dog owners is nuanced. The VMD's regulatory action to date has focused primarily on high-profile enforcement cases and products making explicit medicinal claims, rather than a blanket removal of all CBD pet supplement products from market. Many products continue to be sold in the UK under supplement or feed framings that avoid direct therapeutic claims, existing in a regulatory grey space that the VMD has not yet comprehensively addressed.

This does not mean these products are dangerous — it means their regulatory standing is ambiguous. And ambiguity is a reason for consumers to apply additional scrutiny to quality indicators, not a reason for panic.

The Food Standards Agency and Novel Food Authorisation

For human CBD food products in the UK, the Food Standards Agency (FSA) manages the Novel Food authorisation process. CBD was classified as a Novel Food in the UK (mirroring the EU's 2019 classification) following Brexit, and the FSA has been processing applications from CBD food businesses. Products on the FSA's validated applications list are permitted to remain on sale pending a full safety evaluation; those without validated applications are not.

Importantly, the FSA Novel Food framework applies to human food products, not animal feed. Pet supplements fall under the responsibility of the Animal and Plant Health Agency (APHA) and relevant feed legislation — a separate framework from the human food Novel Food rules, and one where the regulatory picture for CBD specifically remains less clearly mapped.

UK dog owners should be aware that a product's presence on the FSA's validated CBD human food list tells you nothing about its standing as a pet supplement. These are separate regulatory tracks.

EU vs UK Standards Post-Brexit: What Changed and What Matters

Before Brexit, UK pet supplements operated under EU Regulation (EC) No 767/2009 on complementary feedstuffs — the same framework that applies across the EU today. Post-Brexit, Great Britain has retained much of this framework in domestic law, but divergence is occurring as the UK develops independent regulations.

For practical quality assessment purposes, what matters most post-Brexit is not which regulatory flag a product flies, but whether it meets substantive quality standards. In this regard, EU manufacturing under current EU complementary feedstuff regulations remains a meaningful quality benchmark for several reasons:

• Ingredient standards: EU complementary feedstuff regulations require that ingredients appear on the EU feed materials catalogue or have undergone required safety evaluation — a compositional standard that unregistered supplements are not subject to.
• Manufacturing oversight: EU-based manufacturers operating under animal nutrition law are subject to hygiene and quality management requirements under associated EU feed hygiene regulations.
• Labelling requirements: EU complementary feedstuff labelling rules require disclosure of analytical constituents, feeding instructions, and storage conditions in a standardised format — information that helps consumers and vets assess the product.
• THC standards: Products manufactured outside the EU are subject to different (often looser) standards than EU-regulated pet nutrition products, including standards for permissible THC content verification.

UK buyers can legally purchase CBD pet products manufactured in the EU. For those products operating under EU complementary feedstuff regulations, EU manufacturing status carries genuine quality assurance value — arguably more so post-Brexit than before, since the EU framework has continued to develop while UK pet supplement regulation for CBD remains in flux.

What the Science Says: Key Research for UK Dog Owners

The scientific evidence for CBD in dogs has developed considerably since the first controlled trials in the late 2010s. Two studies in particular form the foundation of evidence-based guidance for UK veterinarians and dog owners.

The Cornell Osteoarthritis Study (PMID 30020864)

The 2018 study by Gamble et al. at Cornell University College of Veterinary Medicine remains the most cited controlled trial of CBD in dogs. Administering 2 mg/kg of CBD oil twice daily to dogs with confirmed osteoarthritis, the study found statistically significant improvements in pain scores (assessed via the Canine Brief Pain Inventory) and increased mobility, with no observed adverse effects at this dose. This study used a crossover design with placebo control — the most rigorous study design available for clinical intervention research.

For UK dog owners managing a dog with arthritis or chronic joint pain, this is the strongest evidence base available. The caveat is that it is a single study with a specific dose and product — it cannot be generalised wholesale to all CBD formulations.

Pharmacokinetics Study (PMID 31123969)

The 2019 pharmacokinetics study by Bartner et al. examined how CBD is absorbed, distributed, and eliminated in dogs following three different administration routes. The findings confirmed that oral CBD administration in an oil base achieved the highest bioavailability among the methods tested, and established key data on elimination half-life and dosing interval that inform responsible product formulation.

This study matters for UK dog owners because it is the basis for science-grounded dosing guidance. Brands whose dosing protocols reference or align with this pharmacokinetic data are demonstrating scientific grounding; brands that offer generic "X drops per day" instructions without physiological basis are not.

Quality Standards: What UK Buyers Should Prioritise

Given the regulatory ambiguity in the UK market, quality indicators become especially important as consumer protection tools. The following are non-negotiable for any CBD product you consider giving your dog:

Per-batch Certificate of Analysis from an accredited laboratory

Every production batch should have a corresponding laboratory report from an independent, accredited testing facility. The batch number on the product packaging should map to a specific COA. Some brands do not publish per-batch Certificates of Analysis — you have no way to verify THC content or CBD concentration in the product you purchased. This is an unacceptable gap in transparency for any supplement you are giving to your dog.

THC confirmed below 0.3%

The UK legal threshold for hemp-derived products is 0.3% THC by dry weight. This should be verified on the COA for your specific batch — not relied upon from a general product label claim. For small dogs, even THC at the legal threshold represents a proportionally higher exposure than for large breeds; this is another reason per-batch verification matters.

Veterinary formulation involvement

Without veterinary formulation oversight, dosing guidelines may be based on marketing rather than animal physiology research. Look for explicit statements about veterinary oversight in product development — not just testimonial quotes from individual veterinarians, but documented involvement in formulation design and dosing protocol development.

Natural, high-quality ingredients

A quality CBD supplement for dogs should use natural, hemp-based extract, be free from artificial additives and preservatives, and ideally provide complementary nutritional value — Omega 3 and 6 fatty acids and added vitamins being the most relevant additions for canine health alongside CBD.

The American Veterinary Medical Association (AVMA), while a US body, has published peer-reviewed guidance on cannabis-derived compounds in animals that is widely referenced by UK veterinarians. It is a useful resource for understanding the evidence landscape before your veterinary consultation.

Finding a Vet Who Will Discuss CBD

One practical challenge for UK dog owners is that many veterinarians remain cautious about discussing CBD, partly due to the VMD's classification of therapeutic-claim CBD products as unlicensed veterinary medicines. This can leave owners feeling they cannot raise the question with their vet.

In practice, the conversation is both appropriate and advisable — particularly because CBD inhibits CYP450 liver enzymes, affecting the metabolism of many veterinary medications. If your dog is on phenobarbitone, NSAIDs, or other chronic medications, a veterinary consultation before starting CBD is not optional: it is medically necessary to avoid drug interactions that can significantly alter medication blood levels.

Frame the conversation informatively: bring the COA of the product you are considering, reference the Cornell study (PMID 30020864), and ask specifically about drug interaction risks given your dog's current medications. Most vets will engage productively with a well-prepared, evidence-referenced question.

The Bottom Line for UK Dog Owners

The UK regulatory framework for CBD dog products remains in transition. The VMD's position on therapeutic-claim products is clear; the status of supplement-framed CBD products under UK feed law is less so. Post-Brexit regulatory divergence from the EU adds further complexity.

In this environment, the responsible approach for UK dog owners is to apply rigorous quality criteria independently of regulatory claims — prioritising per-batch COA transparency, EU manufacturing standards, veterinary formulation oversight, and confirmed THC levels. Consult your veterinarian before starting, particularly if your dog is on any existing medication. And choose a product whose brand is willing to be held accountable to the evidence — not just the marketing.

References

1. Gamble LJ, et al. "Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs." Frontiers in Veterinary Science. 2018. PubMed 30020864
2. Bartner LR, et al. "Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs." Can J Vet Res. 2019. PubMed 31123969

Written by Sarah Bennett, Certified Animal Nutritionist. Reviewed by a licensed veterinarian. Last updated June 2026. This article is for informational purposes only and does not constitute veterinary medical advice. Always consult a qualified veterinarian before making changes to your pet's health regimen.